Pozen's migraine machine
With two of its three migraine products in the regulatory process, Pozen Inc. says it is one deal away from reaching breakeven in 2004 with fewer than 30 employees.
The company's latest news was a deal announced last Thursday at the NewsMakers in the Biotech Industry conference, granting Xcel Pharmaceuticals Inc. exclusive rights to market POZN's MT 300 injectable dihydroergotamine mesylate (DHE) to treat severe migraine.
Xcel, which otherwise would have been selling its D.H.E. 45 injection